News

Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug.

Niraparib in combination with abiraterone acetate, and prednisone resulted in a composite response in more than half of all patients.

Use of 18F-rhPSMA-7.3 PET results in post-scan upstaging compared with conventional imaging in patients with prostate cancer recurrence.

Study results may indicate for a potential alternative treatment option to address the unmet needs for elderly patients with newly diagnosed mantle cell lymphoma, according to Michael Wang, MD.

Immune-related adverse effects may show significantly longer progression-free survival and overall survival in patients with metastatic urothelial carcinoma who are receiving pembrolizumab.

Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.

Investigators of the phase 1/2 IMAGINE study, evaluating MT-101 in patients with refractory or relapsed peripheral T-cell lymphoma, have dosed its first patient.

The use of single-agent odronextamab demonstrated a manageable safety profile and promising preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma.

Researchers determined it feasible to distinguish between patients with advanced cancer who remain stable without and with early palliative care by utilizing the novel intervention tool Symptom screening with Targeted Early Palliative care.

The SKYSCRAPER-01 study missed its co-primary end point of progression-free survival in patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer.

Ravi Salgia, MD, PhD, discusses the ways in which oncologists can watch out for non-small cell lung cancer that transforms to small-cell lung cancer.

Findings from a phase 1 study of CART-ddBCMA cells exemplify their safety and ability to induce durable responses in patients with relapsed or refractory multiple myeloma.

Endocrine therapy plus bevacizumab with the possibility of weekly paclitaxel reinduction signals efficacy and demonstrates a good safety profile in patients with ER-positive, HER2-negative advanced or metastatic breast cancer who have responded to induction therapy.

In an interview with Targeted Oncology, Wojciech Jurczak, MD, PhD, discussed the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed or refractory chronic lymphocytic leukemia.

Allegheny Health Network's Allegheny General and Forbes hospitals have earned distinguished 3-star ratings from The Society of Thoracic Surgeons General Thoracic Surgery Database.

More than FCS 40 nurses were nominated by their peers and fellow team members for their superior quality of oncology nursing and leadership capabilities.

The demonstration of clinical benefit of oleclumab or monalizumab added to durvalumab vs durvalumab alone in the COAST study support further evaluation of these combinations in the larger study.

In an interview with Targeted Oncology, Ping Chi, discussed the novel strategy of combining KIT and MEK inhibition to treat patients with GIST treated in the frontline setting.

Breakthrough therapy designation has been granted to repotrectinib by the FDA for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer.

The first participants have been enrolled in the CASCADE-LUNG study, a prospective, multicenter trial.

In an interview with Targeted Oncology, Robert J. Soiffer, MD, discussed the evolving role of stem cell transplant in hematologic malignancies as CAR T-cell therapies begin to reshape treatment landscapes.

The phase 2 VB C-02 trial examining VB10.16 in combination with atezolizumab demonstrated positive results in patients with HPV16-positive advanced cervical cancer.

David Barrington, MD, discusses adjuvant treatments that are currently available for patients with stage 1B, grade 3 endometrial cancer.

Adam Cohen, MD, discussed the recent updates and advancements in BCMA-directed therapies for multiple myeloma.

Although there was no significant overall survival benefit shown with pembrolizumab in the KEYNOTE-177 study, response and safety findings still support its use as a frontline option for patients with microsatellite instability high and mismatch repair deficient metastatic colorectal cancer.

Nazli Dizman, MD, discusses what community oncologists should keep in mind about gut microbiome when treating their patients.

As these new techniques evolve and we adjust conditioning regimens, induction timing and dosing levels, as well as introducing different drug combinations, we are very hopeful that we will continue to see improved outcomes for hematologic malignancies, says Guenther Koehne, MD, PhD.

Production of lutetium Lu 177 vipivotide tetraxetan and Luthathera have been temporarily suspended due to potential quality issues identified in their manufacturing processes.

The phase 2 clinical trial of the combination therapy, GT90001 and nivolumab, for the treatment of patients with advanced hepatocellular carcinoma has dosed its first patient.

Patients with chronic graft-versus-host disease who received a full series of the SARS-CoV-2 vaccine showed varied immune responses, regardless of their baseline characteristics.